Stock comparison
BridgeBio Pharma
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BBIO
BridgeBio Pharma
Market cap
$13.54B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BBIO | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 24F | 66C | RPRX |
| Benjamin Graham | 18F | 84A | RPRX |
| Philip Fisher |
Side-by-side metrics
| Metric | BBIO | RPRX |
|---|---|---|
| Market cap | $13.54B | $23.44B |
| P/E (TTM) | - | 27.6x |
| EV/EBIT | - | 19.9x |
| ROIC (TTM) | -57.94% | 8.43% |
| Gross margin | 93.78% | 99.95% |
| Net margin | -125.17% | 33.91% |
| Revenue CAGR 5y | 63.82% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BBIO leads on
- Debt / Equity-vs 1.3x+187%
- EV/EBIT-vs 19.9x+174%
- P/E (TTM)-vs 27.6x+164%
- Revenue CAGR 5y63.82%vs 0.96%
More like RPRX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.